Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bishal Gyawali

Showing results (1-10 of 296) with videos related to

Pageof 30
Sort By:
Ecancermedicalscience|January 2, 2018
The OlympiAD trial: who won the gold?Bishal Gyawali
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?Bishal Gyawali
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular CarcinomaBishal Gyawali
Nature Medicine|June 1, 2026
Downplaying toxicities in cancer drug trials is not acceptableBishal Gyawali
Nature Reviews. Clinical Oncology|July 17, 2023
Problematic crossovers in cancer drug trialsBishal Gyawali
Clinical Advances in Hematology & Oncology : H&O|July 8, 2022
Lessons learned from the accelerated approval of cancer drugsBishal Gyawali
Journal of Global Oncology|July 19, 2017
Me, TooBishal Gyawali
Recenti Progressi in Medicina|May 12, 2017
Biosimilars in oncology: everybody agrees but nobody uses?Bishal Gyawali
The Lancet. Oncology|May 5, 2018
Does global oncology need artificial intelligence?Bishal Gyawali
Eclinicalmedicine|February 28, 2023
Letter to Editor-response: placebo response ratesBishal Gyawali
Pageof 30

Showing results (1-10 of 296) with videos related to

Sort By:
Pageof 30
Ecancermedicalscience|January 2, 2018
The OlympiAD trial: who won the gold?Bishal Gyawali
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?Bishal Gyawali
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular CarcinomaBishal Gyawali
Nature Medicine|June 1, 2026
Downplaying toxicities in cancer drug trials is not acceptableBishal Gyawali
Nature Reviews. Clinical Oncology|July 17, 2023
Problematic crossovers in cancer drug trialsBishal Gyawali
Clinical Advances in Hematology & Oncology : H&O|July 8, 2022
Lessons learned from the accelerated approval of cancer drugsBishal Gyawali
Journal of Global Oncology|July 19, 2017
Me, TooBishal Gyawali
Recenti Progressi in Medicina|May 12, 2017
Biosimilars in oncology: everybody agrees but nobody uses?Bishal Gyawali
The Lancet. Oncology|May 5, 2018
Does global oncology need artificial intelligence?Bishal Gyawali
Eclinicalmedicine|February 28, 2023
Letter to Editor-response: placebo response ratesBishal Gyawali
Pageof 30